EUVIMEDEUVIMED entdecken
Open Access

Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia

Nicola Maciocia iD, Malika Hoekx iD, Ciaran Acuna iD, Brandon Wade iD, Amy Burley iD, Saumya Ramanayake iD, Francesco Nannini iD, Patrycja A Wawrzyniecka, Thaneswari Karpanasamy iD, Maria Schuldt iD, Stephanie Ng iD, Mathieu Ferrari iD und 9 weitere

Science Translational Medicine · 2025

DOI: 10.1126/scitranslmed.adr1476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2025. Verfasst von Nicola Maciocia und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with relapsed/refractory (r/r) T cell acute lymphoblastic leukemia (T-ALL) have a dismal prognosis, highlighting the urgent need for effective therapies. Chimeric antigen receptor (CAR)–T cell approaches targeting pan–T cell antigens may be limited by T cell aplasia and fratricide, necessitating “rescue” allogeneic hematopoietic stem cell transplantation. In this study, we identify CD21, a pan–B cell marker, as a promising target for T-ALL immunotherapy. CD21 is expressed in 50% of T-ALL cases at diagnosis but in fewer than 10% of mature T cells. We observed that CAR-T cells targeting membrane-distal CD21 epitopes were ineffective, likely because of the bulky, glycosylated nature of the antigen. However, when we engineered CAR-T cells to target membrane-proximal CD21 epitopes using an antigen-binding fragment (Fab)–CAR design, we demonstrated robust activity against T-ALL cell lines, primary tumors, and patient-derived xenografts in both in vitro and in vivo models. The enhanced efficacy of this Fab-CAR design was driven by its high stability and reduced surface expression, addressing limitations of traditional CAR constructs. In addition, pharmacological inhibition of the phosphatidylinositol 3-kinase axis up-regulated CD21 expression in T-ALL, further enhancing the potency of anti-CD21 CAR-T cells in vitro and in a patient-derived xenograft in vivo model. This study establishes CD21 as a viable CAR-T target and highlights advances in CAR design for bulky antigens, as well as the potential for pharmacological strategies to augment target expression. Anti-CD21 CAR-T cells represent a promising therapeutic option for improving outcomes for patients with T-ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenPrecursor T-Cell Lymphoblastic Leukemia-LymphomaT-LymphocytesHumansAnimalsCell Line, TumorXenograft Model Antitumor AssaysMiceImmunotherapy, AdoptiveMice, Inbred NODMice, SCID

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Haematology, Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK.
  • Autolus Ltd., Mediaworks, 191 Wood Lane, White City, London W12 7FP, UK.
  • Department of Haematology, Ospedale Papa Giovanni XXIII, Piazza OMS 1, 24127 Bergamo, Italy.

ORCID-Profile: Nicola Maciocia, Malika Hoekx, Ciaran Acuna, Brandon Wade, Amy Burley, Saumya Ramanayake, Francesco Nannini, Thaneswari Karpanasamy, Maria Schuldt, Stephanie Ng, Mathieu Ferrari, Teresa Marafioti, Giuseppe Gritti, David O'Connor, Lydia Lee, Marc Mansour, Asim Khwaja, Martin Pule, Paul Maciocia

Förderung

  • Medical Research Council
  • Cancer Research UK

Zitieren

APA

Maciocia, N., Hoekx, M., Acuna, C., Wade, B., Burley, A., Ramanayake, S., Nannini, F., Wawrzyniecka, P. A., Karpanasamy, T., Schuldt, M., Ng, S., Ferrari, M., Marafioti, T., Gritti, G., Onuoha, S., O'Connor, D., Lee, L., Mansour, M., Khwaja, A., …, & Maciocia, P. (2025). Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adr1476

Vancouver

Maciocia N, Hoekx M, Acuna C, Wade B, Burley A, Ramanayake S, et al. Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia. Science Translational Medicine. 2025. doi:10.1126/scitranslmed.adr1476

BibTeX
@article{Maciocia2025,
  author = {Maciocia, Nicola and Hoekx, Malika and Acuna, Ciaran and Wade, Brandon and Burley, Amy and Ramanayake, Saumya and Nannini, Francesco and Wawrzyniecka, Patrycja A and Karpanasamy, Thaneswari and Schuldt, Maria and Ng, Stephanie and Ferrari, Mathieu and Marafioti, Teresa and Gritti, Giuseppe and Onuoha, Shimobi and O'Connor, David and Lee, Lydia and Mansour, Marc and Khwaja, Asim and Pule, Martin and Maciocia, Paul},
  title = {Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia},
  journal = {Science Translational Medicine},
  year = {2025},
  doi = {10.1126/scitranslmed.adr1476}
}
Kostenlos starten →